Accéder au contenu
Merck
Toutes les photos(1)

Documents

C2150000

Cholécalciférol

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(+)-Vitamine D3, 7-Déhydrocholestérol activé, 7-déhydrocholestérol activé, Cholécalciférol

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C27H44O
Numéro CAS:
67-97-0
Poids moléculaire :
384.64
Numéro Beilstein :
2339331
Numéro MDL:
MFCD00078131
Code UNSPSC :
41116107
ID de substance PubChem :
329774967
Nomenclature NACRES :
NA.24

Source biologique

synthetic

Qualité

pharmaceutical primary standard

Agence

EP

Famille d'API

cholecalciferol

Forme

solid

Fabricant/nom de marque

EDQM

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Pf

83-86 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

−20°C

Chaîne SMILES 

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

Clé InChI

QYSXJUFSXHHAJI-YRZJJWOYSA-N

Informations sur le gène

human ... VDR(7421)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Cholecalciferol, also referred to as vitamin D3, promotes the absorption of calcium and phosphorus in the body to regulate bone growth. It is most commonly found in humans and animals and is produced in our skin when exposed to sunlight. It is used to treat and prevent bone disorders (such as rickets, osteomalacia).

Application

Cholecalciferol for system suitability may be used as an analytical reference standard for the determination of the analyte in pharmaceutical formulations by liquid chromatography.

Actions biochimiques/physiologiques

La vitamine D fonctionne à travers une récepteur qui fait partie de la famille des facteurs de transcription dépendant du ligand. Module la prolifération et la différentiation des cellules à la fois cancéreuses et normales. A des effets antiprolifératifs et anti-métastatiques sur les cellules cancéreuses de poumons, du colon et de la prostate. Les récepteurs activés de la vitamine D de l′intestin et des os maintiennent l′absorbance du calcium et l′homeostase.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H300 + H310 + H330,H372

Classification des risques

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Cholecalciferol
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 246(6), 2058-2059 (2013)
Hongliu Ding et al.
Neurology, 81(17), 1531-1537 (2013-09-27)
To conclusively test for a specific association between the biological marker 25-hydroxy-vitamin D3, a transcriptionally active hormone produced in human skin and liver, and the prevalence and severity of Parkinson disease (PD). We used liquid chromatography/tandem mass spectrometry to establish
Bich Tran et al.
The American journal of clinical nutrition, 99(1), 156-161 (2013-10-11)
Observational data suggested that supplementation with vitamin D could reduce risk of infection, but trial data are inconsistent. We aimed to examine the effect of oral vitamin D supplementation on antibiotic use. We conducted a post hoc analysis of data
Ian R Reid et al.
Lancet (London, England), 383(9912), 146-155 (2013-10-15)
Findings from recent meta-analyses of vitamin D supplementation without co-administration of calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, or because the intervention was not targeted to deficient populations. Despite these data, almost half
Sara S Oberhelman et al.
Mayo Clinic proceedings, 88(12), 1378-1387 (2013-12-03)
To determine whether a single monthly supplement is as effective as a daily maternal supplement in increasing breast milk vitamin D to achieve vitamin D sufficiency in their infants. Forty mothers with exclusively breast-fed infants were randomized to receive oral
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique